By disrupting mitochondrial functions , Saleh’s anti-cancer molecule destroys a cell from the inside while keeping the outer shell of the cell intact. How the cell dies makes all the difference.

MaveriX Oncology has developed the IMPACT-2X platform for the design of first-in-class small-molecule therapeutics—which are conditionally activated by highly expressed hydroxylases in cancer ...

In the 1980s, a promising new drug target emerged in the battle against cancer. Known as c-Myc, the protein is encoded by one of the first cellular oncogenes discovered in humans and has since been ...